propionyl carnitine | 17298-38-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: propionyl carnitine
• 英文别名: 3-Carboxy-N,N,N-trimethyl-2-(propanoyloxy)propan-1-aminium；(3-carboxy-2-propanoyloxypropyl)-trimethylazanium
• CAS: 17298-38-3
• 化学式: C₁₀H₂₀NO₄
• 分子量: 218.273
• InChiKey: UFAHZIUFPNSHSL-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] PANTETHENOYLCYSTEINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE PANTÉTHÉNOYLCYSTÉINE ET LEURS UTILISATIONS
  申请人：COMET THERAPEUTICS INC

  公开号：WO2020198573A1

  公开（公告）日：2020-10-01

  The present disclosure relates to compounds of Formula (I) or (II): (Formulae (I), (II)), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

  本公开涉及式(I)或(II)的化合物：(式(I)，(II))，以及其药用可接受的盐或溶剂化合物。本公开还涉及包含这些化合物的药物组合物，以及这些化合物和药物组合物的治疗和诊断用途。
• Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof
  申请人：Goel Om P

  公开号：US20090012160A1

  公开（公告）日：2009-01-08

  The present invention discloses novel dual prodrug compounds of formula (1), methods for their preparation and intermediates in their syntheses, formula (1): wherein A is a single bond, —O—, or —CH 2 —; m and n vary independently and are an integer from 1 to 15; p and q vary from 0 to an integer from 1 to 4; B is a single bond or —CR 3 R 4 ; D is formula (2): or formula (3): and X is halogen; R 1 to R 4 are various substituents selected to optimize the physiochemical and biological properties such as, lipophilicity, bioavailability, and pharmacokinetics of compounds of Formula 1; and R 1 and R 2 or R 3 and R 4 may optionally be tethered together to form a 3- to 7-membered alicyclic ring. These compounds are useful for the treatment of various infections, metabolic, cardiovascular and neurological disorders.

  本发明披露了一种新颖的双重前药化合物，其化学式为(1)，以及它们的制备方法和合成中间体，其中A为单键，-O-或-CH2-；m和n独立变化，均为1至15的整数；p和q变化为0或1至4的整数；B为单键或-CR3R4；D为式(2)或式(3)；X为卤素；R1至R4为各种取代基，选取以优化化合物的物理化学和生物学特性，如脂溶性、生物利用度和药代动力学；R1和R2或R3和R4可选择性地被连接在一起形成3至7个成员的脂环。这些化合物可用于治疗各种感染、代谢、心血管和神经系统疾病。
• Amino Acid Compounds
  申请人：Kramer Ronald

  公开号：US20120220643A1

  公开（公告）日：2012-08-30

  A method for increasing the vasodilative characteristics of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, Phenylalanine, Carnitine, Taurine, and Betaine.

  本发明公开了一种增加氨基酸在人类或动物体内扩张血管特性的方法。该方法包括向人类或动物体内给予一种药物有效量的氨基酸化合物，所述氨基酸化合物基本上由从天冬氨酸、半胱氨酸、甘氨酸、赖氨酸、蛋氨酸、脯氨酸、酪氨酸、苯丙氨酸、肉碱、牛磺酸和甜菜碱组成的氨基酸的硝酸盐或亚硝酸盐所选。
• Method of safely administering nitrate dietary supplements and compositions
  申请人：ThermoLife International, LLC

  公开号：US10646508B1

  公开（公告）日：2020-05-12

  A method of making a composition or a dietary supplement is provided, the method comprising combining a quantity of a Nitrate with a quantity of an Amino Acid Compound, wherein the combining of the Nitrate with the Amino Acid Compound reduces a side effect or toxicity of the Nitrate. Also provided is a method of safely administering to a subject a Nitrate with a reduced side effect or toxicity, the method comprising: combining a quantity of the Nitrate with a quantity of an Amino Acid Compound in a composition or a dietary supplement, wherein the combining of the Nitrate with the Amino Acid Compound reduces the side effect or toxicity of the Nitrate; and safely administering to the subject the composition or dietary supplement comprising the Nitrate with the reduced side effect or toxicity.

  提供了一种制造组合物或膳食补充剂的方法，该方法包括将一定量的硝酸盐与一定量的氨基酸化合物结合，其中硝酸盐与氨基酸化合物的结合降低了硝酸盐的副作用或毒性。还提供了一种向受试者安全施用副作用或毒性降低的硝酸盐的方法，该方法包括：在组合物或膳食补充剂中将一定量的硝酸盐与一定量的氨基酸化合物结合，其中硝酸盐与氨基酸化合物的结合降低了硝酸盐的副作用或毒性；以及向受试者安全施用包含副作用或毒性降低的硝酸盐的组合物或膳食补充剂。
• Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds
  申请人：Pisano Claudio

  公开号：US20070190128A1

  公开（公告）日：2007-08-16

  Esters of L-carnitine and alkanoyl L-carnitines are described which can be used as cationic lipids for the intracellular delivery of pharmacologically active compounds. New esters of L-carnitine and alkanoyl L-carnitines of formula (I) are also disclosed wherein the R groups are as defined in the description.